Groenewegen A. Rutten F.H. Mosterd A. et al.

Epidemiology of heart failure.

Eur J Heart Fail. 2020; 22: 1342-1356View in Article Google ScholarShah K.S. Xu H. Matsouaka R.A. et al.

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.

J Am Coll Cardiol. 2017; 70: 2476-2486View in Article Google ScholarGreene S.J. Butler J. Albert N.M. et al.

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

J Am Coll Cardiol. 2018; 72: 351-366View in Article Google ScholarMaddox T.M. Januzzi J.L. Allen L.A. et al.

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.

J Am Coll Cardiol. 2021; 77: 772-810View in Article Google ScholarPacker M. Butler J. Zannad F. et al.

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Circulation. 2021; 144: 1284-1294View in Article Google ScholarMonica Reddy R.P. Inzucchi S.E.

SGLT2 inhibitors in the management of type 2 diabetes.

Endocrine. 2016; 53: 364-372View in Article Google ScholarHeerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.

Dapagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med. 2020; 383: 1436-1446View in Article Google ScholarZannad F. Ferreira J.P. Pocock S.J. et al.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Lancet. 2020; 396: 819-829View in Article Google ScholarPacker M. Anker S.D. Butler J. et al.

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

Circulation. 2021; https://doi.org/10.1161/CIRCULATIONAHA.120.051783View in Article Google ScholarMcMurray J.J.V. Solomon S.D. Inzucchi S.E. et al.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

N Engl J Med. 2019; 381: 1995-2008View in Article Google ScholarDixit N. Shah S. Ziaeian B. et al.

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization.

US Cardiology Review. 2021; 15: e07View in Article Google ScholarBerg D.D. Jhund P.S. Docherty K.F. et al.

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.

JAMA Cardiol. 2021; https://doi.org/10.1001/jamacardio.2020.7585View in Article Google ScholarLopaschuk G.D. Verma S.

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

JACC Basic Transl Sci. 2020; 5: 632-644View in Article Google ScholarPacker M.

What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?.

Eur Heart J. 2019; 41: 1757-1763View in Article Google ScholarYancy C.W. Jessup M. Bozkurt B. et al.

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

J Am Coll Cardiol. 2013; 62: e147-e239View in Article Google ScholarSantos-Gallego C.G. Vargas-Delgado A.P. Requena J.A. et al.

Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction.

J Am Coll Cardiol. 2020; https://doi.org/10.1016/j.jacc.2020.11.008View in Article Google ScholarSantos-Gallego Carlos G. Requena-Ibanez Juan A. San Antonio R. et al.

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

J Am Coll Cardiol. 2019; 73: 1931-1944View in Article Google ScholarBurnier M. Brunner H.R.

Neurohormonal consequences of diuretics in different cardiovascular syndromes.

Eur Heart J. 1992; 13: 28-33View in Article Google ScholarDamman K. Beusekamp J.C. Boorsma E.M. et al.

Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).

Eur J Heart Fail. 2020; 22: 713-722View in Article Google ScholarGriffin M. Rao V.S. Ivey-Miranda J. et al.

Empagliflozin in Heart Failure.

Circulation. 2020; 142: 1028-1039View in Article Google ScholarHartupee J. Mann D.L.

Neurohormonal activation in heart failure with reduced ejection fraction.

Nat Rev Cardiol. 2017; 14: 30-38View in Article Google ScholarMazer C.D. Hare G.M.T. Connelly P.W. et al.

Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Circulation. 2020; 141: 704-707View in Article Google ScholarSanthanam A.V. d'Uscio L.V. Katusic Z.S.

Cardiovascular effects of erythropoietin an update.

Adv Pharmacol. 2010; 60: 257-285View in Article Google ScholarGroenveld H.F. Januzzi J.L. Damman K. et al.

Anemia and mortality in heart failure patients a systematic review and meta-analysis.

J Am Coll Cardiol. 2008; 52: 818-827View in Article Google ScholarGreene S.J. Butler J. Fonarow G.C.

Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed.

JAMA Cardiol. 2021; 6: 743-744View in Article Google ScholarDocherty K.F. Jhund P.S. Inzucchi S.E. et al.

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.

Eur Heart J. 2020; 41: 2379-2392View in Article Google ScholarVoors A.A. Angerman C.E. Teerlink J.R. et al.

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomzied trial.

Nat Med. 2022; 28: 568-574View in Article Google ScholarShen L. Kristensen S.L. Bengtsson O. et al.

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

JACC: Heart Fail. 2021; 9: 254-264View in Article Google ScholarFerreira J.P. Zannad F. Pocock S.J. et al.

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.

J Am Coll Cardiol. 2021; 77: 1397-1407View in Article Google ScholarWheeler D.C. Stefansson B.V. Batiushin M. et al.

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.

Nephrol Dial Transpl. 2020; 35: 1700-1711View in Article Google ScholarMcGuire D.K. Shih W.J. Cosentino F. et al.

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

JAMA Cardiol. 2021; 6: 148-158View in Article Google ScholarKario K. Ferdinand K.C. Vongpatanasin W.

Are SGLT2 Inhibitors New Hypertension Drugs?.

Circulation. 2021; 143: 1750-1753View in Article Google ScholarBöhm M. Anker Stefan D. Butler J. et al.

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.

J Am Coll Cardiol. 2021; 78: 1337-1348View in Article Google ScholarSerenelli M. Böhm M. Inzucchi S.E. et al.

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).

Eur Heart J. 2020; 41: 3402-3418View in Article Google ScholarRao V.N. Murray E. Butler J. et al.

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.

J Am Coll Cardiol. 2021; 78: 2004-2012View in Article Google ScholarOtto C.M. Nishimura R.A. Bonow R.O. et al.

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.

J Am Coll Cardiol. 2021; https://doi.org/10.1016/j.jacc.2020.11.018View in Article Google ScholarBergethon K.E. Ju C. DeVore A.D. et al.

Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry.

Circ Heart Fail. 2016; 9https://doi.org/10.1161/circheartfailure.115.002594View in Article Google ScholarPandey A. Patel K.V. Liang L. et al.

Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry.

JAMA Cardiol. 2018; 3: 489-497View in Article Google ScholarPacker M. Anker S.D. Butler J. et al.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

N Engl J Med. 2020; 383: 1413-1424View in Article Google ScholarBhatt D.L. Szarek M. Steg P.G. et al.

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

N Engl J Med. 2021; 384: 117-128View in Article Google ScholarHonigberg M.C. Vardeny O. Vaduganathan M.

Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.

Circ Heart Fail. 2020; 13: e006623View in Article Google ScholarWadhera R.K. Joynt Maddox K.E. Wasfy J.H. et al.

Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia.

Jama. 2018; 320: 2542-2552View in Article Google ScholarIsaza N. Calvachi P. Raber I. et al.

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.

JAMA Netw Open. 2021; 4: e2114501View in Article Google ScholarAnderson J.L. Heidenreich P.A. Barnett P.G. et al.

ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

J Am Coll Cardiol. 2014; 63: 2304-2322View in Article Google ScholarGaziano T.A. Fonarow G.C. Claggett B. et al.

Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.

JAMA Cardiol. 2016; 1: 666-672View in Article Google ScholarGaziano T.A. Fonarow G.C. Velazquez E.J. et al.

Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.

JAMA Cardiol. 2020; https://doi.org/10.1001/jamacardio.2020.2822View in Article Google ScholarHsu J.J. Ziaeian B. Fonarow G.C.

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.

JACC Heart Fail. 2017; 5: 763-771View in Article Google ScholarAnker S.D. Butler J. Filippatos G. et al.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

N Engl J Med. 2021; 385: 1451-1461View in Article Google Scholar